Feed/Companies/Vaderis Therapeutics

Vaderis Therapeutics

As of 14 Oct 2026, Vaderis Therapeutics has raised $152M across 1 verified round on record; latest: $152 million Series B led by Goldman Sachs Alternatives and TCGX, announced 11 Aug 2026.

BUILT ON

Visit site

Breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases.

vaderis.comLinkedInBasel, Switzerland

LATEST ROUND

Series B

$152M · 2026-08-11

RAISED ON RECORD · USD

$152M

across 1 verified round

INVESTORS

2 leads

SOURCES

from 1 publisher

Rounds

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$152M · 2026-08-11

[ HISTORY ]

led by Goldman Sachs Alternatives, TCGX

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$152M	2026-08-11	Goldman Sachs Alternatives, TCGX	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source Leads added Goldman Sachs Alternatives, TCGX · prnewswire.com

Vaderis Therapeutics

Rounds

Company

Rounds

Sources

Profile

Investors

Vaderis Therapeutics

Rounds

Profile

Sources

Series B$152M2026-08-111 source

Investors

Series B$152M2026-08-118 investors